| Literature DB >> 31665058 |
Matthew D Bigelow1, Abbas Z Kouzani2.
Abstract
Epilepsy affects nearly 1% of the world's population. A third of epilepsy patients suffer from a kind of epilepsy that cannot be controlled by current medications. For those where surgery is not an option, neurostimulation may be the only alternative to bring relief, improve quality of life, and avoid secondary injury to these patients. Until recently, open loop neurostimulation was the only alternative for these patients. However, for those whose epilepsy is applicable, the medical approval of the responsive neural stimulation and the closed loop vagal nerve stimulation systems have been a step forward in the battle against uncontrolled epilepsy. Nonetheless, improvements can be made to the existing systems and alternative systems can be developed to further improve the quality of life of sufferers of the debilitating condition. In this paper, we first present a brief overview of epilepsy as a disease. Next, we look at the current state of biomarker research in respect to sensing and predicting epileptic seizures. Then, we present the current state of open loop neural stimulation systems. We follow this by investigating the currently approved, and some of the recent experimental, closed loop systems documented in the literature. Finally, we provide discussions on the current state of neural stimulation systems for controlling epilepsy, and directions for future studies.Entities:
Keywords: Biomarkers; Closed loop stimulation; Refractory epilepsy
Mesh:
Substances:
Year: 2019 PMID: 31665058 PMCID: PMC6820988 DOI: 10.1186/s12984-019-0605-x
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Fig. 1Basic Seizure detection flow [19]
Approved invasive stimulation methods for epilepsy. Replicated from [70]
| Data | Vagus nerve stimulation | Thalamic stimulation | Responsive focus stimulation |
|---|---|---|---|
| Approval | 1997 (FDA)/(EU) (also heart rate triggered closed loop since 2015) | 2011 (EU) | 2013 (FDA) |
| Stimulation site | Left vagus nerve (neck) | Anterior nuclei of the thalamus (bilaterally) | Epileptic focus (cortex) |
| Stimulator placement | Subcutaneous, left pectoral/sub clavicular | Subcutaneous, abdominal | Within the skull |
| Stimulation mode | Open-loop/closed-loop based on detection of tachycardia | Open-loop | Closed-loop based on detection of ictal EEG patterns |
| Stimulus parameters | Intensity: 0.25–3 mA Frequency: 20–30 Hz Pulse width: 250–500 μs Duty cycle: 30 s on/ 5 min off (standard); 7 s on/30 s off (“rapid cycling”) | Intensity: 5 V Frequency: 145 Hz Pulse width: 95 μs Duty cycle: 1 min on/5 min off | Intensity: ∼1 mA Frequency: 200 Hz Pulse width: 160 μs Duty cycle: ∼5.9 min/day; (closed loop) |
| Side effects of implantation | 1.6% infections 1% vocal cord paralysis | 12,7% infections 10.9% local pain 18.2% paraesthesia at implantation site 4.5% in cranial bleeding | 7.8% infections 4.7% intracranial bleeding |
| Side effects of stimulation | Hoarseness (intensity-dependent up to 66%) Cough (up to 45%) | 14.8% depression 13.0% memory impairment | No statistics |
Approved open and closed loop stimulation devices for the treatment of epilepsy and reported efficacy
| Data | Vagus nerve stimulation | Vagus nerve stimulation | Thalamic stimulation | Responsive focus stimulation |
|---|---|---|---|---|
| Stimulation site | Left vagus nerve (neck) | Left vagus nerve (neck) | Anterior nuclei of the thalamus (bilaterally) | Epileptic focus (cortex) |
| Stimulator placement | Subcutaneous, left pectoral/sub clavicular | Subcutaneous, left pectoral/sub clavicular | Subcutaneous, abdominal | Within the skull |
| Stimulation mode | Open-loop 5 m off 30s on | Closed-loop based on detection of tachycardia | Open-loop 5 m on 1 m off | Closed-loop based on detection of ictal EEG patterns |
| Seizure reduction | b30.43% at 12 months 62.68% at 6 years [ | a66% at 13 months [ | c41% at year 1 69% at year 5 [ | 60% year 3 66% year 6 [ |
| Responder rate | b49% at time of last follow up | a59% at 13 months [ | c43% at year 1 68% at year 5 [ | 58% year 3 59% year 6 [ |
| Effectiveness of detection/prediction algorithm | None used | No results have been given | None used | No results have been given |
aValues are reported as mean values of the total new implant cohort
bMean length of treatment time was 4.10 years with a maximum treatment time of 12 years
cValues reported are median values of 110 patients